Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome
NCT ID: NCT00514501
Last Updated: 2016-03-31
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
510 participants
INTERVENTIONAL
2007-05-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Utilization of Diagnostic Ultrasound in the Detection and Therapy of Acute Coronary Syndromes
NCT00955136
Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
NCT00126438
Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
NCT00126425
123I-mIBG SPECT Imaging
NCT02043522
Effect of Colchicine On Left Ventricle Function After Anterior Myocardial Infarction Assessed By Speckle Tracking
NCT05200052
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Iodofiltic Acid I 123
Iodofiltic acid I 123
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Iodofiltic acid I 123
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are 40 years of age or older.
* Are being evaluated for possible ACS.
* If female, then not of childbearing potential as documented by history or has a negative serum or urine pregnancy test within 4 hours prior to receiving the test drug and agrees to use an acceptable form of birth control.
Exclusion Criteria
* Females who are pregnant or lactating.
* History of left ventricular ejection fraction (LVEF)=40%.
* History of MI.
* Acute ST segment elevation on ECG.
* Left bundle branch block on ECG.
* Known history of significant allergy to x-ray contrast media or iodine/iodides.
* Currently or formerly on medication that targets fatty acid uptake or metabolism, eg ranolazine, (Ranexa).
* Administered radiopharmaceutical other than rubidium-82 or thallium-201 within 2 days prior to study enrollment.
* Underwent cardiac stress testing of any kind within 2 days prior to study enrollment.
* Serum creatinine level \>2.0 mg per dL.
* Received investigational compound and/or medical device within 30 days of admission into this study.
* Q-wave abnormalities consistent with previous MI
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Molecular Insight Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Norman LaFrance, MD
Role: STUDY_DIRECTOR
Molecular Insight Pharmaceuticals, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Huntsville, Alabama, United States
Mesa, Arizona, United States
Los Angeles, California, United States
Mission Viejo, California, United States
Newport Beach, California, United States
Roseville, California, United States
Hartford, Connecticut, United States
New Haven, Connecticut, United States
Newark, Delaware, United States
Jacksonville, Florida, United States
Aurora, Illinois, United States
Maywood, Illinois, United States
Louisville, Kentucky, United States
Auburn, Maine, United States
Bethesda, Maryland, United States
Detroit, Michigan, United States
Royal Oak, Michigan, United States
Troy, Michigan, United States
Minneapolis, Minnesota, United States
Kansas City, Missouri, United States
Lebanon, New Hampshire, United States
Manchester, New Hampshire, United States
Albany, New York, United States
Brooklyn, New York, United States
Kingston, New York, United States
New York, New York, United States
Rochester, New York, United States
Syracuse, New York, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Providence, Rhode Island, United States
Houston, Texas, United States
Richmond, Virginia, United States
Madison, Wisconsin, United States
North Vancouver, British Columbia, Canada
Scarborough Village, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kontos MC, Dilsizian V, Weiland F, DePuey G, Mahmarian JJ, Iskandrian AE, Bateman TM, Heller GV, Ananthasubramaniam K, Li Y, Goldman JL, Armor T, Kacena KA, LaFrance ND, Garcia EV, Babich JW, Udelson JE. Iodofiltic acid I 123 (BMIPP) fatty acid imaging improves initial diagnosis in emergency department patients with suspected acute coronary syndromes: a multicenter trial. J Am Coll Cardiol. 2010 Jul 20;56(4):290-9. doi: 10.1016/j.jacc.2010.03.045.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MIP-BP23
Identifier Type: -
Identifier Source: org_study_id
NCT00585663
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.